|
1
|
Lantz PM and Booth KM: The social
construction of the breast cancer epidemic. Soc Sci Med.
46:907–918. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Michels KB, Solomon CG, Hu FB, Rosner BA,
Hankinson SE, Colditz GA and Manson JE; Nurses' Health Study, :
Type 2 diabetes and subsequent incidence of breast cancer in the
Nurses' Health Study. Diabetes Care. 26:1752–1758. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Houssami N, Turner RM and Morrow M:
Meta-analysis of pre-operative magnetic resonance imaging (MRI) and
surgical treatment for breast cancer. Breast Cancer Res Treat.
165:273–283. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pogoda K, Niwińska A, Murawska M and
Pieńkowski T: Analysis of pattern, time and risk factors
influencing recurrence in triple-negative breast cancer patients.
Med Oncol. 30:3882013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nichols HB, Trentham-Dietz A, Egan KM,
Titus-Ernstoff L, Holmes MD, Bersch AJ, Holick CN, Hampton JM,
Stampfer MJ, Willett WC, et al: Body mass index before and after
breast cancer diagnosis: associations with all-cause, breast
cancer, and cardiovascular disease mortality. Cancer Epidemiol
Biomarkers Prev. 18:1403–1409. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Slattery ML, Herrick JS, Mullany LE,
Samowitz WS, Sevens JR, Sakoda L and Wolff RK: The co-regulatory
networks of tumor suppressor genes, oncogenes, and miRNAs in
colorectal cancer. Genes Chromosomes Cancer. 56:769–787. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schueller F, Roy S, Vucur M, Trautwein C,
Luedde T and Roderburg C: The Role of miRNAs in the pathophysiology
of liver diseases and toxicity. Int J Mol Sci. 19:22612018.
View Article : Google Scholar
|
|
8
|
Wu SG, Huang YJ, Bao B, Wu LM, Dong J, Liu
XH, Li ZH, Wang XY, Wang L, Chen BJ, et al: miR-508-5p acts as an
anti-oncogene by targeting MESDC1 in hepatocellular carcinoma.
Neoplasma. 64:40–47. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gao W, Li W, Xiao T, Liu XS and Kaelin WG
Jr: Inactivation of the PBRM1 tumor suppressor gene amplifies the
HIF-response in VHL-/-clear cell renal carcinoma. Proc Natl Acad
Sci USA. 114:1027–1032. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang H, Wang Q, Zhao Q and Di W: MiR-124
inhibits the migration and invasion of ovarian cancer cells by
targeting SphK1. J Ovarian Res. 6:842013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y,
Li C, Chong M, Ibrahim T, Mercatali L, et al: miR-126 and miR-126*
repress recruitment of mesenchymal stem cells and inflammatory
monocytes to inhibit breast cancer metastasis. Nat Cell Biol.
15:284–294. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mariotto AB, Etzioni R, Hurlbert M,
Penberthy L and Mayer M: Estimation of the number of women living
with metastatic breast cancer in the United States. Cancer
Epidemiol Biomarkers Prev. 26:809–815. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alakwaa FM, Chaudhary K and Garmire LX:
Deep learning accurately predicts estrogen receptor status in
breast cancer metabolomics data. J Proteome Res. 17:337–347. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Notaridou M, Quaye L, Dafou D, Jones C,
Song H, Høgdall E, Kjaer SK, Christensen L, Høgdall C, Blaakaer J,
et al Australian Ovarian Cancer Study Group/Australian Cancer Study
(Ovarian Cancer); Ovarian Cancer Association Consortium, : Common
alleles in candidate susceptibility genes associated with risk and
development of epithelial ovarian cancer. Int J Cancer.
128:2063–2074. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ye D, Li Z and Wei C: Genistein inhibits
the S-phase kinase-associated protein 2 expression in breast cancer
cells. Exp Ther Med. 15:1069–1075. 2018.PubMed/NCBI
|
|
17
|
Meindl A, Hellebrand H, Wiek C, Erven V,
Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L,
Schaal H, et al: Germline mutations in breast and ovarian cancer
pedigrees establish RAD51C as a human cancer susceptibility gene.
Nat Genet. 42:410–414. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li S, Mei Z, Hu HB and Zhang X: The lncRNA
MALAT1 contributes to non-small cell lung cancer development via
modulating miR-124/STAT3 axis. J Cell Physiol. 233:6679–6688. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dong LL, Chen LM, Wang WM and Zhang LM:
Decreased expression of microRNA-124 is an independent unfavorable
prognostic factor for patients with breast cancer. Diagn Pathol.
10:452015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Danesh H, Hashemi M, Bizhani F, Hashemi SM
and Bahari G: Association study of miR-100, miR-124-1, miR-218-2,
miR-301b, miR-605, and miR-4293 polymorphisms and the risk of
breast cancer in a sample of Iranian population. Gene. 647:73–78.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baldassari F, Zerbinati C, Galasso M,
Corrà F, Minotti L, Agnoletto C, Previati M, Croce CM and Volinia
S: Screen for MicroRNA and drug interactions in breast cancer cell
lines points to miR-126 as a modulator of CDK4/6 and PIK3CA
inhibitors. Front Genet. 9:1742018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu ZJ, Li Y, Wu YZ, Wang Y, Nian WQ, Wang
LL, Li LC, Luo HL and Wang DL: Long non-coding RNA CCAT2 promotes
the breast cancer growth and metastasis by regulating TGF-β
signaling pathway. Eur Rev Med Pharmacol Sci. 21:706–714.
2017.PubMed/NCBI
|
